Cell therapy manufacturing has been a complex, challenging and costly process, but a new manufacturing solution seeks to change that
Reproducible freezing and thawing is critical for successful cell therapies. GE Healthcare’s G. John Morris explains why.
As cell therapies continue to transition from the discovery stage to therapeutic reality, with further approvals sure to come, new challenges are emerging.
Once upon a time people wondered whether cell therapies would make it. Now, the industry is surging forward with new questions and even more creative solutions – takeaways from ISCT 2018, Montreal.
The FDA approval of two cell therapies is a major milestone on an exciting journey of discovery. What are some of the important questions still being explored?
Manufacturing viral vector-based therapies such as vaccines and gene and cell therapies is complex, but a new manufacturing solution helps solve those challenges.
China is quickly becoming a world leader in biopharma, with rapid build-out of gene and cell therapy production capacity and a robust pipeline of drugs in development.
|
|
|
|
|
|
|
|
|